David Sherr
Profiles

David H. Sherr, PhD

Professor, Environmental Health - Boston University School of Public Health

(617) 638-6464
dsherr@bu.edu
Housman (R Bldg) - R-408
View Full Profile at BUMC

Biography

如果

Ag)

While the Sherr laboratory has historically been oriented towards understanding the biologic effects of environmental chemicals to prevent cancer and to understand the basic molecular mechanisms behind cancer aggression and immunosuppression, it has most recently begun investigating how to detect the changes in cells that precede cancer formation and how to intercept cancer at these inflection points before it develops. To this end, the laboratory is now exploiting its proprietary AhR inhibitors and advanced gene editing techniques to boost anti-cancer immunity and to block transformation of benign cells into malignant cells. The lab is currently funded by grants from the NIH, The Find The Cause Breast Cancer Foundation (https://findthecausebcf.org/)(a private foundation dedicated to finding the causes of cancer and strategies to prevent cancer), and the Hahnemann Foundation.

博士

Other Positions

  • Professor, Pathology & Laboratory Medicine - Boston University Chobanian & Avedisian School of Medicine
  • Member, BU-BMC Cancer Center - Boston University
  • Member, Amyloidosis Center - Boston University
  • Member, Evans Center for Interdisciplinary Biomedical Research - Boston University
  • Member, Genome Science Institute - Boston University
  • Director, Superfund Research Program - Boston University
  • Director, Immunology Training Program - Boston University
  • Graduate Faculty (Primary Mentor of Grad Students) - Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences

Education

  • Cornell University, PhD Field of Study: Microbiology
  • Brandeis University, BA Field of Study: Biology

Websites

Classes Taught

  • SPHEH713

Publications

  • Published on 2/19/2025

    Haarmann-Stemmann T, Reichert D, Coumoul X, Lawrence BP, Perdew GH, Sherr DH, Weighardt H, Rolfes KM, Esser C. The Janus-facedness of the aryl hydrocarbon receptor pathway Report of the 6th International AHR Meeting: Research, Prevention, Therapy. Biochem Pharmacol. 2025 Feb 19; 234:116808. PMID: 39983850.

     Read At: PubMed
  • Published on 11/4/2024

    Hahn ME, Sherr DH. The enigmatic AHRR: beyond aryl hydrocarbon receptor repression. J Leukoc Biol. 2024 Nov 04; 116(5):915-918. PMID: 39030724.

     Read At: PubMed
  • Published on 8/13/2024

    Snyder M, Wang Z, Lara B, Fimbres J, Pichardo T, Mazzilli S, Khan MM, Duggineni VK, Monti S, Sherr DH. The Aryl Hydrocarbon Receptor Controls IFN?-Induced Immune Checkpoints PD-L1 and IDO via the JAK/STAT Pathway in Lung Adenocarcinoma. bioRxiv. 2024 Aug 13. PMID: 39185148.

     Read At: PubMed
  • Published on 3/14/2023

    Perdew GH, Esser C, Snyder M, Sherr DH, van den Bogaard EH, McGovern K, Fernández-Salguero PM, Coumoul X, Patterson AD. The Ah Receptor from Toxicity to Therapeutics: Report from the 5th AHR Meeting at Penn State University, USA, June 2022. Int J Mol Sci. 2023 Mar 14; 24(6). PMID: 36982624.

     Read At: PubMed
  • Published on 3/14/2023

    Perdew GH, Esser C, Snyder M, Sherr DH, van den Bogaard EH, McGovern K, Fernández-Salguero PM, Coumoul X, Patterson AD. The Ah Receptor from Toxicity to Therapeutics: Report from the 5th AHR Meeting at Penn State University, USA, June 2022. Int J Mol Sci. 2023 Mar 14; 24(6). PMID: 36982624.

     Read At: PubMed
  • Published on 1/4/2022

    Arinze NV, Yin W, Lotfollahzadeh S, Napoleon MA, Richards S, Walker JA, Belghasem M, Ravid JD, Hassan Kamel M, Whelan SA, Lee N, Siracuse JJ, Anderson S, Farber A, Sherr D, Francis J, Hamburg NM, Rahimi N, Chitalia VC. Tryptophan metabolites suppress the Wnt pathway and promote adverse limb events in chronic kidney disease. J Clin Invest. 2022 01 04; 132(1). PMID: 34752422.

     Read At: PubMed
  • Published on 5/11/2021

    Kenison JE, Wang Z, Yang K, Snyder M, Quintana FJ, Sherr DH. The aryl hydrocarbon receptor suppresses immunity to oral squamous cell carcinoma through immune checkpoint regulation. Proc Natl Acad Sci U S A. 2021 05 11; 118(19). PMID: 33941684.

     Read At: PubMed
  • Published on 3/8/2021

    Koual M, Tomkiewicz C, Guerrera IC, Sherr D, Barouki R, Coumoul X. Aggressiveness and Metastatic Potential of Breast Cancer Cells Co-Cultured with Preadipocytes and Exposed to an Environmental Pollutant Dioxin: An in Vitro and in Vivo Zebrafish Study. Environ Health Perspect. 2021 03; 129(3):37002. PMID: 33683140.

     Read At: PubMed
  • Published on 12/31/2020

    Wang Z, Snyder M, Kenison JE, Yang K, Lara B, Lydell E, Bennani K, Novikov O, Federico A, Monti S, Sherr DH. How the AHR Became Important in Cancer: The Role of Chronically Active AHR in Cancer Aggression. Int J Mol Sci. 2020 Dec 31; 22(1). PMID: 33396563.

     Read At: PubMed
  • Published on 11/25/2020

    Kenison JE, Jhaveri A, Li Z, Khadse N, Tjon E, Tezza S, Nowakowska D, Plasencia A, Stanton VP, Sherr DH, Quintana FJ. Tolerogenic nanoparticles suppress central nervous system inflammation. Proc Natl Acad Sci U S A. 2020 12 15; 117(50):32017-32028. PMID: 33239445.

     Read At: PubMed

View 228 more publications:View Full Profile at BUMC

News & In the Media

View all profiles